SCM
CRVS icon

Stonepine Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Stonepine Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-46,886
Closed -$125K – 32
2021
Q2 		$125K Sell
46,886
-269,393
-85% -$742K 0.07% 24
2021
Q1 		$974K Buy
+316,279
New +$1.14M 0.53% 25

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Stonepine Capital Management's CRVS Position: Q3 2021 in Review

Stonepine Capital Management sold out of Corvus Pharmaceuticals (CRVS) in Q3 2021, closing a stake of 46,886 shares — an estimated $125K sold.

Stonepine Capital Management first reported a position in CRVS in Q1 2021 and held it in 2 quarters. The position peaked at $974K in Q1 2021. 61 funds tracked by Wall St. Rank hold CRVS as of Q3 2021.

  • Stonepine Capital Management reported no remaining Corvus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Stonepine Capital Management sold 46,886 Corvus Pharmaceuticals shares in Q3 2021, an estimated $125K.
  • Stonepine Capital Management first reported a position in Corvus Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Stonepine Capital Management's Corvus Pharmaceuticals position peaked at $974K in Q1 2021.
  • 61 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2021.

Based on Stonepine Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.